EXPLORING THE UNINTENDED CONSEQUENCES OF MISUSE OF WEGOVY AND OZEMPIC IN WEIGHT MANAGEMENT: A COMPREHENSIVE REVIEW
DOI:
https://doi.org/10.22159/ijpps.2024v16i6.50611Keywords:
GLP-1 receptor agonists, Obesity pharmacotherapy, Weight management, Metabolic health, Adverse events, Patient-centered careAbstract
In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as promising options for weight management, offering not only glycemic control benefits but also significant reductions in body weight. Among these agents, Wegovy (semaglutide) and Ozempic (semaglutide) have gained attention for their efficacy in promoting weight loss, even in individuals without diabetes. However, the off-label use of these medications for weight management raises several questions and concerns regarding their safety, efficacy, and long-term effects. This comprehensive review aims to explore the complexities of GLP-1 agonists in weight management, focusing on their mechanism of action, clinical evidence, safety profile, dosing considerations, potential interactions, and future directions.
Downloads
References
Lexchin J, Mintzes B. Semaglutide: a new drug for the treatment of obesity. Drug Ther Bull. 2023 Oct 25;61(12):182-8. doi: 10.1136/dtb.2023.000007, PMID 37879878.
Ashinze P, Abdul Rahman T, Wireko AA. Semaglutide in the spotlight: weighing benefits against rising concerns. Ther Adv Endocrinol Metab. 2024 Jan;15:20420188231222394. doi: 10.1177/20420188231222394, PMID 38188532.
Basch CH, Narayanan S, Tang H, Fera J, Basch CE. Descriptive analysis of TikTok videos posted under the hashtag #Ozempic. J Med Surg Public Health. 2023;1:100013, doi: 10.1016/j.glmedi.2023.100013.
Abdi Beshir S, Ahmed Elnour A, Soorya A, Parveen Mohamed A, Sir Loon Goh S, Hussain N. A narrative review of approved and emerging anti-obesity medications. Saudi Pharm J. 2023 Oct;31(10):101757. doi: 10.1016/j.jsps.2023.101757, PMID 37712012.
Wojtara M, Syeda Y, Mozgała N, Mazumder A. Examining off-label prescribing of Ozempic for Weight-Loss Qeios Ltd; 2023. doi: 10.32388/t6y97s.
Lau DC, Batterham RL, le Roux CW. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev Clin Pharmacol. 2022 Mar 4;15(3):251-67. doi: 10.1080/17512433.2022.2070473, PMID 35466848.
Borzutzky C, King E, Fox CK, Stratbucker W, Tucker J, Yee JK. Trends in prescribing anti‐obesity pharmacotherapy for paediatric weight management: data from the POWER Work Group. Pediatr Obes. 2021;16(1):e12701. doi: 10.1111/ijpo.12701, PMID 32877010.
Villela R, Correa R. Semaglutide 2.4 Mg: the latest GLP-1RA approved for obesity. J Investig Med. 2022 Jan;70(1):3-4. doi: 10.1136/jim-2021-002227, PMID 34949728.
Campbell JE, Müller TD, Finan B, DiMarchi RD, Tschop MH, D’Alessio DA. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023 Sep;35(9):1519-29. doi: 10.1016/j.cmet.2023.07.010, PMID 37591245.
Alsefri KA, Alsefri MA, Alsefri MA, Alharbi AS, Ozempic (Semaglutide). A new weight loss drug for chronic weight management. Green Publication; 2022 Mar 14. Journal of Population Therapeutics and Clinical Pharmacology; 2022. p. 1604-7. doi: 10.53555/jptcp.v29i03.4454.
Bham A, Ditta MA. Semaglutide for the treatment of obesity–a review. World Family Medicine Journal/Middle East Journal of Family Medicine. 2021;19(9). doi: 10.5742/mewfm.2021.94116.
Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V. Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: a systematic review and meta‐analysis of randomized controlled trials. Wiley; 2023 Nov 29. doi: 10.1111/dom.15382.
Hale PM, Ali AK, Buse JB, McCullen MK, Ross DS, Sabol ME. Medullary thyroid carcinoma surveillance study: a case-series registry. Thyroid. 2020 Oct 1;30(10):1397-8. doi: 10.1089/thy.2019.0591, PMID 32316860.
Han SH, Ockerman K, Furnas H, Mars P, Klenke A, Ching J. Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss. Oxford University Press (OUP); 2023 Dec 12. doi: 10.1093/asj/sjad364.
Thompson T, Rahman H, Sprando A, Friedlander MP. In overweight adult patients with type 2 diabetes, is tirzepatide as effective for weight loss compared to existing GLP1 agonists (i.e. Ozempic)? Evid Based Pract. 2023 Aug 11;27(2):23-5, doi: 10.1097/EBP.0000000000001948.
Aslam U, Mehboob S. Misuse of ozempic as a drug choice for weight loss, a potential threat. Int J Sci Rep. 2023 Nov 23;9(12):419. doi: 10.18203/issn.2454-2156.IntJSciRep20233563.
Winter G. The risks and rewards of semaglutide in obesity treatment. Journal of Prescribing Practice. 2023 Apr 2;5(4):146-7. doi: 10.12968/jprp.2023.5.4.146.
Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol [Internet]. 2022 Sep 14;13:935823. doi: 10.3389/fphar.2022.935823, PMID 36188627.
Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Springer Science+Business Media LLC; 2023 Aug 19. doi: 10.7759/cureus.43773.
Sharma A, Parachuri N, Kumar N, Saboo B, Tripathi HN, Kuppermann BD. Semaglutide and the risk of diabetic retinopathy-current perspective. Eye (Lond). 2022;36(1):10-1. doi: 10.1038/s41433-021-01741-5, PMID 34373613.
Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022 Oct 20;10:996179. doi: 10.3389/fpubh.2022.996179, PMID 36339230.
Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med. 2023 Jan 18;12(3):772. doi: 10.3390/jcm12030772, PMID 36769420.
Tariq MA, Amin H, Shurjeel Q, Gang A, Mohiuddin A. Gastrointestinal adverse events of semaglutide in patients with overweight or obesity. Eur J Intern Med. 2022 Dec;106:138-9. doi: 10.1016/j.ejim.2022.08.015, PMID 35985949.
Ruder K. As semaglutide’s popularity soars, rare but serious adverse effects are emerging. JAMA. 2023 Dec 12;330(22):2140-2. doi: 10.1001/jama.2023.16620, PMID 37966850.
Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022 Apr 14;134Suppl1:5-17. doi: 10.1080/00325481.2022.2147326, PMID 36691309.
Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022 Dec 1;28(15)Suppl:S297-306. doi: 10.37765/ajmc.2022.89293, PMID 36525677.
Jones PM, Hobai IA, Murphy PM. Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution! Can J Anaesth. 2023 Jul 19;70(8):1281-6. doi: 10.1007/s12630-023-02550-y, PMID 37466910.
Suran M. As ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. JAMA. 2023 May 16;329(19):1627-9. doi: 10.1001/jama.2023.2438, PMID 37099334.
Schmitz S, Tchang BG, Shukla AP. Obesity pharmacotherapy: a review of current practices and future directions. Curr Treat Options Gastro. 2023 Feb 8;21(1):27-47. doi: 10.1007/s11938-023-00409-1.
PubChem. Semaglutide. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/56843331 [Last accessed on 04 May 2024]
Elberry AA, Rabea H, Mohsen SM, Mourad AR, Kinawy G. Prospective study on the effect of pharmaceutical care on maternal and fetal outcomes in gestational and pregestational diabetic patients. Int J Pharm Pharm Sci. 2022;14(5):42-8. doi: 10.22159/ijpps.2022v14i5.43598.
Kulmi M, Saxena G. Comparison of effects of sitagliptin and a combination of naltrexone and bupropion in high fat diet-induced obesity model in rats. Asian J Pharm Clin Res. 2022;15(8):119-23. doi: 10.22159/ajpcr.2022.v15i8.45002.
Kolhe RC, Chaudhari RY. Development and evaluation of antidiabetic polyherbal tablet using medicinal plants of traditional use. Int J Curr Pharm Sci. 2023;15(2):17-21. doi: 10.22159/ijcpr.2023v15i2.2095.
Published
How to Cite
Issue
Section
Copyright (c) 2024 SARTHAK A. KUTE, MADHURA S. CHOTHAVE, PRAJAKTA B. ROTE, ANUPAMA A. KAPADNIS, VAISHNAVI V. KALE
This work is licensed under a Creative Commons Attribution 4.0 International License.
